Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201

Core Insights - Immix Biopharma has initiated the U.S. NEXICART-2 trial for NXC-201, a CAR-T cell therapy targeting AL Amyloidosis, with the first patient dosed at Memorial Sloan Kettering Cancer Center [1][3] - The NEXICART-2 study aims to evaluate the safety and efficacy of NXC-201 in relapsed/refractory AL Amyloidosis patients, building on positive results from the NEXICART-1 trial which reported a 92% overall response rate [2][4] - NXC-201 is the only CAR-T therapy currently in development for AL Amyloidosis, with the potential to become a first-in-class treatment [3][7] Company Overview - Immix Biopharma is a clinical-stage biopharmaceutical company focused on cell therapies for AL Amyloidosis and autoimmune diseases, with NXC-201 as its lead candidate [9] - The company has received Orphan Drug Designation for NXC-201 in both the U.S. and EU [7][9] Clinical Trials - NEXICART-2 is a Phase 1b/2 trial designed to enroll 40 patients with adequate cardiac function who have not received prior BCMA-targeted therapy, evaluating two doses of NXC-201 [4] - The primary endpoints of the trial include complete response rate and overall response rate, following consensus recommendations [4] Market Context - The prevalence of relapsed/refractory AL Amyloidosis in the U.S. is estimated to grow at 12% per year, reaching approximately 33,277 patients in 2024 [8] - The amyloidosis market was valued at $3.6 billion in 2017 and is projected to reach $6 billion by 2025 [8]